Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | DHPS | P49366 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20259741 | 0.80 | AXL (0.46) | AXLIDO1METAP2NOS1TRPA1 | |
| SCHEMBL10285272 | 0.76 | AXL (0.62) | AXLIDO1METAP2NOS1TRPA1 | |
| SCHEMBL13266980 | 0.75 | KDM4E (0.46) | AXLIDO1JAK2KDM4EGAA | |
| SCHEMBL2627058 | 0.74 | AXL (0.68) | AXLIDO1METAP2NOS1TRPA1 | |
| SCHEMBL2616447 | 0.70 | KDM4E (0.52) | AXLIDO1TRPA1JAK2KDM4E | |
| SCHEMBL26825623 | 0.69 | AXL (0.43) | AXLIDO1METAP2NOS1JAK2 | |
| SCHEMBL24654996 | 0.68 | CYP1A2 (0.41) | AXLTRPA1JAK2PDPK1CYP1A2 | |
| SCHEMBL4540970 | 0.68 | KDM4E (0.48) | AXLIDO1JAK2KDM4EGAA | |
| SCHEMBL12683720 | 0.68 | AXL (1.00) | AXLIDO1METAP2NOS1TRPA1 | |
| SCHEMBL23797047 | 0.68 | KDM4E (0.53) | AXLIDO1TRPA1JAK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190119214-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | AXL 2049/4885IDO1 274/4885METAP2 1146/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | AXL 2000/4885IDO1 352/4885METAP2 1460/4885 |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | AXL 2674/4885IDO1 234/4885METAP2 885/4885 |
| US-20190119214-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | AXL 132/4885IDO1 1555/4885METAP2 1644/4885 |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | AXL 132/4885IDO1 1555/4885METAP2 1644/4885 |
| US-10597366-B2 | Aryl ethers and uses thereof | HIF1AN, EGLN2, VHL | AXL 132/4885IDO1 1555/4885METAP2 1644/4885 |
| US-10807948-B2 | Aromatic compounds and uses thereof | VHL, HIF1AN, HIF1A | AXL 1416/4885IDO1 257/4885METAP2 2657/4885 |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | HIF1A, HIF1AN, VHL | AXL 1381/4885IDO1 1609/4885METAP2 3037/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | AXL 2674/4885IDO1 234/4885METAP2 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.